Key Highlights

  • Merck (NYSE:MRK) and Daiichi Sankyo voluntarily withdrew the Accelerated Approval application for ifinatamab deruxtecan on September 25, 2026, so no FDA decision is expected around the previously listed October 10 date.
  • The application covered adults with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy, using the 187-patient IDeate-Lung01 Phase 2 trial.
  • After discussions with the FDA, the companies concluded the dataset does not meet the requirements for accelerated approval for the proposed indication, and released no efficacy or safety numbers.
  • The Phase 3 IDeate-Lung02 trial is nearly fully enrolled, and Daiichi Sankyo and Merck (NYSE:MRK) will assess a possible new filing after its results are known.

What Happened

On September 25, 2026 Daiichi Sankyo and Merck (NYSE:MRK) announced they had voluntarily withdrawn the Biologics license application for ifinatamab deruxtecan, known as I-DXd, in extensive-stage small cell lung cancer after the disease worsened on or after platinum chemotherapy. The submission sought accelerated approval. A calendar of October FDA decisions still listed October 10 for the drug, and a summary dated October 5 noted that no decision is expected. This is not a new development from October 7, as the row that prompted this article suggested. The Withdrawal followed discussions with the FDA, and Merck (NYSE:MRK) said it was disappointed that the dataset did not support approval at this time.

Why Accelerated Approval Was Not Enough

Accelerated approval lets the FDA clear a drug for serious diseases on an early measure, here objective response rate, if it is reasonably likely to predict benefit. IDeate-Lung01 was a global, randomized, open-label Phase 2 study of 187 patients who had one to three prior lines of therapy, testing doses of 8 mg/kg and 12 mg/kg every three weeks before expanding at 12 mg/kg. The primary endpoint was response rate by blinded independent central review. The companies did not report the results, so the reason the FDA found the data lacking is not public. Marjorie Green of Merck Research Laboratories said the dataset did not support approval now, and the companies still plan further studies in lung and other cancers.

Risks and What to Watch

A withdrawal delays any US launch and removes a near-term catalyst for the program. The Phase 3 IDeate-Lung02 trial, comparing I-DXd with physician's choice chemotherapy in relapsed disease, is nearly fully enrolled, and a positive outcome could support a fresh filing, though no timeline was given. Two other Phase 3 trials, IDeate-Prostate01 and IDeate-Esophageal01, continue in prostate cancer and esophageal squamous cell cancer. Merck (NYSE:MRK) has a broad portfolio, so the setback is one part of a much larger business. Watch for Phase 3 data timing, any FDA feedback and whether the program moves to a different regulatory path. The stock reaction was not verified, and no price move is cited here. Merck's next Quarterly Report is the likely place for further commentary. This is not Investment advice.

Where Things Stand

There is no FDA ruling on October 10 because Merck (NYSE:MRK) and Daiichi Sankyo withdrew the application on September 25, 2026, after the agency indicated the Phase 2 data were not enough for accelerated approval. The news is two weeks old, and the programme continues through Phase 3 trials. The balance of evidence is a delay, not a termination. The next catalyst is IDeate-Lung02, which is nearly fully enrolled.